Summary
IDEXX Laboratories, Inc. reported solid financial results for the second quarter of 2019, demonstrating continued revenue growth driven primarily by its Companion Animal Group (CAG) segment. Total revenue increased by 6.8% year-over-year to $620.1 million, with organic revenue growth of 8.7%. Net income attributable to stockholders rose to $125.7 million, a significant increase from $108.7 million in the prior year period, translating to diluted earnings per share of $1.43 compared to $1.23. The company continues to see strong performance in recurring revenue within its CAG segment, particularly from consumables and reference laboratory services, supported by an expanding instrument installed base. While the LPD segment experienced a slight revenue decrease due to market factors like African Swine Fever and reduced bovine testing, the overall financial health remains robust, bolstered by effective cost management and operational efficiencies. The company also highlighted its liquidity position and reaffirmed its financial guidance, indicating confidence in its ongoing strategy and ability to generate shareholder value.
Financial Highlights
52 data points| Revenue | $620.10M |
| Cost of Revenue | $262.25M |
| Gross Profit | $357.85M |
| R&D Expenses | $32.26M |
| Operating Income | $164.28M |
| Interest Expense | $8.19M |
| Net Income | $125.70M |
| EPS (Basic) | $1.46 |
| EPS (Diluted) | $1.43 |
| Shares Outstanding (Basic) | 86.22M |
| Shares Outstanding (Diluted) | 87.61M |
Key Highlights
- 1Total revenue for the quarter increased by 6.8% to $620.1 million, with organic revenue growth of 8.7%, indicating strong underlying business performance.
- 2Net income attributable to IDEXX stockholders grew by 15.6% to $125.7 million, with diluted EPS rising to $1.43 from $1.23 year-over-year.
- 3The Companion Animal Group (CAG) segment remains the primary growth driver, with revenue up 7.9% and organic revenue growth of 9.5%, fueled by strong demand for diagnostics, consumables, and services.
- 4CAG Diagnostics recurring revenue showed robust growth of 9.1%, driven by IDEXX VetLab consumables and reference laboratory services, reflecting continued market penetration and customer adoption.
- 5Operating income increased by 12.8% to $164.3 million, demonstrating effective cost management and operational leverage.
- 6The company maintained a strong liquidity position with $110.8 million in cash and cash equivalents and significant availability under its revolving credit facility.
- 7Despite some segment-specific headwinds (e.g., LPD segment revenue down 5.4%), the overall diversified business model and strong CAG performance led to positive consolidated results.